GSK India Sales Growth Falters In Battle With Retailers Over Margins
This article was originally published in PharmAsia News
A continuing battle between India retailers and drug makers has led to complaints by GlaxoSmithKline and others of boycotts on some of their products that began in mid-September, leading to reduced sales.
You may also be interested in...
FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.